#I-Tech #Selektope #medetomidine

The Urgent Call for Regulatory Reform in EU Shipping Sector

In a landscape increasingly dictated by environmental sustainability and stringent climate targets, the European Union (EU) finds itself grappling with serious internal contradictions as highlighted by the Swedish biotech firm, I-Tech. I-Tech specializes in innovative marine antifouling solutions, notably its product Selektope®, which has piqued the attention of environmentalists and economists alike due to its low biocide effectiveness and its potential implications for both the shipping industry and Europe’s climate commitments.

Concerning Developments: Regulatory Shortcomings

On October 27, 2025, I-Tech presented compelling evidence to the European Commission, arguing that the current processes for assessing and renewing the active substance medetomidine contained in Selektope® are fundamentally flawed. According to the firm, these processes are rooted in misleading scientific data, which could stifle innovation and hinder the EU's ability to achieve its climate objectives. In particular, the existing framework is hampering the competitive edge of European shipyards and manufacturers of marine coatings at a critical juncture when global competition intensifies. This scenario is alarming, given that many EU members see maritime transport as vital for reducing carbon emissions.

The Misclassification of Medetomidine

A significant issue raised by I-Tech involves the erroneous classification of medetomidine as an endocrine disruptor, a designation that warrants a re-evaluation. The regulators have categorized it based on its pharmaceutical usage rather than its marine application, a distinction that is crucial. This misinterpretation has led to the perception that there are adequate alternative substances available, when in truth, they fall short by not adequately addressing the specific fouling problems presented by barnacles, which Selektope® effectively combats.

Markus Jönsson, CEO of I-Tech, asserted,